API CAS 105628-07-7 Fasudil Hcl Fasudil
Product Description
Product Details
| Product Name |
Fasudil |
| Appearance |
Fasudil Powder |
| Assay |
>99% |
| MW |
327.83 |
| MF |
C14H18ClN3O2S |
| PSA |
70.68 |
| LogP |
4.17 |
Fasudil hydrochloride, a unique calcium antagonist and vasodilator, is primarily used to treat cerebral vasospasm after subarachnoid hemorrhage (SAH). Unlike traditional calcium channel blockers that only regulate calcium influx through the cell membrane, fasudil acts intracellularly to relax vascular smooth muscle by inhibiting myosin light chain kinase and protein kinase C. It effectively reduces severe angiographic and symptomatic vasospasm, as well as cerebral infarction, without lowering systemic blood pressure. Additionally, fasudil is being investigated in clinical trials for acute ischemic stroke, cerebrovascular disease sequelae, and angina pectoris.
Application&Function
Fasudil hydrochloride, developed by Asahi Kasei Corporation (Japan), is a novel cardiovascular and cerebrovascular drug with broad pharmacological effects. It promotes nerve function recovery, alleviates clinical symptoms, and reduces disability rates, making it particularly valuable for ischemic cerebrovascular diseases such as cerebral vasospasm following subarachnoid hemorrhage. While ultra-early thrombolytic therapy is often inaccessible at the grassroots level due to economic constraints and limited disease awareness, fasudil hydrochloride plays a crucial role in reconstructing local blood circulation within the treatment time window, preventing disease progression. Its significant neuroprotective and therapeutic effects make it well-suited for clinical use, especially in resource-limited settings, to lower disability rates, reduce mortality, and improve patients' quality of life.
Specification
){kind=link}